Lexaria Bioscience announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of human afflictions, including neurological disorders, cardiovascular conditions, cancer, autoimmune disease, and many new possibilities; studies are investigating the efficacy of GLP-1 drugs on kidney disease, liver disease, bone health and even aging. With so many proven and potential blockbuster indications, enhanced delivery and increased efficacy would supercharge the impact of GLP-1 agonists. Lexaria Bioscience Corp intends to do just that with its patented DehydraTECH platform developed to improve the way active molecules enter the bloodstream upon oral ingestion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LEXX:
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
- Lexaria Bioscience announces final results from human pilot study of DehydraTECH
- Lexaria expects to file IND application for hypertension trial within 45 days
- Lexaria Bioscience files to sell 1.62M shares of common stock for holders
- Lexaria announces additional results from human pilot study of DehydraTECH